DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Authors: Dr Anes Yang, Clinical Researcher, Department of Dermatology, St George Hospital, University of New South Wales, Sydney, NSW, Australia; Dr Monisha Gupta, Senior Staff Specialist, Department of Dermatology, Liverpool Hospital, Sydney, NSW, Australia. DermNet NZ Medical Editor: Dr Delwyn Dyall-Smith, Dermatologist, Wagga Wagga, NSW, Australia. DermNet NZ Editor in Chief: Adjunct Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell. September 2018.
Quinacrine is a derivative of quinine, synthesised from the bark of the cinchona tree. It was extensively used as an antimalarial agent for millions of servicemen in the Pacific region during the 1940s. It was found to be well tolerated and has subsequently been used for the treatment of connective tissue diseases, such as lupus erythematosus. However, due to yellowish skin changes that occur after long-term use, it is not used as commonly as hydroxychloroquine or chloroquine [1,2].
Quinacrine is also known as mepacrine and has the brand name Atabrine™.
The use of quinacrine in dermatology has been mostly superseded by chloroquine and hydroxychloroquine . Although it can be used alone, quinacrine is usually used in combination with hydroxychloroquine to boost response in recalcitrant inflammatory skin conditions such as:
Quinacrine may be preferred in patients at ocular risk or those with profound fatigue as it is a central nervous system stimulant . It is also useful in those who are unable to tolerate chloroquine derivatives.
Quinacrine has been shown to have the following effects.
Quinacrine is rapidly absorbed from the gastrointestinal tract following oral administration. The plasma concentration of quinacrine increases rapidly during the first week and equilibrates by the fourth week. Quinacrine is slowly excreted, mainly via the kidneys [1,3].
Quinacrine is dispensed as 100 mg tablets. The recommended maintenance dose is 100 mg orally daily, or on alternate days in fair-skinned patients due to possible skin discolouration. The onset of action is 3–6 weeks, depending on the initial dose. If there has been no improvement after 8 weeks, then the quinacrine should be ceased .
Quinacrine is often combined with hydroxychloroquine, when hydroxychloroquine alone is ineffective (eg, hydroxychloroquine 200–400 mg daily with 50–100 mg quinacrine every second day).
Quinacrine is an older medication and is no longer marketed in Australia but is available through the Australian Therapeutic Goods Administration's Special Access Scheme. It is not available in New Zealand.
Quinacrine is generally well tolerated. Common minor adverse effects such as transient headache, gastrointestinal symptoms (eg, nausea, abdominal cramping, and diarrhoea), and dizziness, improve with time or a reduction in the dose [1,3].
Quinacrine commonly causes yellowing and bruise-like discolouration of the skin, oral mucosa, nails, and sclera that is not related to liver injury. This discolouration is more prominent in fair-skinned patients but is harmless and will fade when the treatment is stopped [1,3]. Dermatitis is another common skin complaint that resolves with the discontinuation of quinacrine .
High doses of quinacrine, usually exceeding those used in dermatology, can cause more serious side effects. These side effects include corneal oedema (> 500 mg/days), neurological issues (1200 mg/days), liver toxicity, and aplastic anaemia . Although the latter has rarely been reported in doses of quinacrine < 300 mg/day, routine blood test monitoring is recommended. The aplastic anaemia is often preceded by a lichen planus-like rash.
Quinacrine crosses into the placenta; therefore, should not be given to pregnant women, or women planning a pregnancy (see DermNet NZ's pages on Safety of medicines taken during pregnancy and on Lactation and the skin).
Quinacrine is excreted in small amounts in breast milk. Although problems have not been reported, its use during breastfeeding should be avoided if possible.
Children tolerate quinacrine less well than adults and it may cause vomiting due to its bitter taste.
Appropriate studies in elderly populations have not been performed for quinacrine; however, no geriatric-specific problems have been documented.
Women planning a pregnancy, and pregnant and lactating women should not take quinacrine.
Caution should be taken in:
© 2020 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.